logo
Plus   Neg
Share
Email

Proteostasis Therapeutics Inc. (PTI) Is Surging On Study Results

Proteostasis Therapeutics Inc. (PTI) announced after the close Wednesday that its Phase 1 study of PTI-801 and PTI-808 in the treatment of cystic fibrosis achieved statistical significance on all endpoints.

Proteostasis Therapeutics gapped open sharply higher Thursday morning and has continued to rise in early trade. Shares are now up 5.11 at $7.00 on strong volume. The stock has surged to a 7-month high.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 and under

0 Articles
Follow RTT